Brain gamma-aminobutyric acid, but not glutamine and glutamate levels are lower in older adults with chronic musculoskeletal pain: considerations by sex and brain location

Yenisel Cruz-Almeida a,b,c,d,x, Megan Forbes c,e, Ronald C. Cohen c,e, Adam J. Woods c,e, Roger B. Fillingim a,b, Joseph L. Riley III a,b, Eric S. Porges c,e

Abstract
Introduction and Objectives: GABAergic and glutamatergic neurotransmitter systems are central to the pathophysiology of chronic pain and are equally affected by aging processes. We measured levels of frontal gamma-aminobutyric acid (GABA) and the combined resonance of glutamate and glutamine (Glx) in vivo using proton magnetic resonance spectroscopy (1H-MRS) to elucidate age-specific and pain-specific associations with clinical and experimental pain in older adults.

Methods: Younger (18–24, n = 24) and older (60–94, n = 41) individuals part of a larger study (Neuromodulatory Examination of Pain and Mobility Across the Lifespan [NEPAL]) underwent questionnaires, quantitative sensory testing, and 1H-MRS Mescher-Garwood point-resolved spectroscopy to measure GABA and Glx levels in prefrontal and sensorimotor brain regions.

Results: Older participants had significantly lower sensorimotor, but not prefrontal, GABA and Glx levels, compared with younger controls (P's, 0.05). Younger controls had significantly higher prefrontal and sensorimotor GABA, but not Glx, levels compared with older controls and older adults with chronic pain (P's < 0.05). Older males with chronic pain had significantly lower prefrontal GABA compared with older and younger male controls (P's < 0.05). Prefrontal GABA, but not Glx, was significantly associated with self-reported and experimental pain measures (P's < 0.05). Our results are the first to focus exclusively on age and pain differences in GABA and Glx including younger and older controls to elucidate aging and pain contributions to brain GABAergic and glutamatergic processes.

Conclusion: Evaluation of both the neuroinhibitory and neuroexcitatory mechanisms provide promising potential for improving both our understanding of the mechanisms of chronic pain in aging and opportunities for effective, individualized treatments.

Keywords: GABA, brain, MRS, musculoskeletal pain, aging

1. Introduction
Chronic pain in older individuals is a growing public health problem that negatively affects physical and cognitive function, ultimately decreasing quality of life and overall well-being. Furthermore, effective pain treatments are lacking for this vulnerable population and the identification of potential neurobiological mechanisms underlying these pain conditions may potentially reveal effective therapeutic targets. Of particular relevance to the field of pain and aging neurobiology is the ability to measure the brain’s major inhibitory and excitatory neurochemicals: gamma-aminobutyric acid (GABA) and the combined resonance of glutamate and glutamine (Glx) using the Mescher-Garwood point-resolved spectroscopy (MEGA-PRESS) sequence in proton magnetic resonance spectroscopy (1H-MRS). To date, this method has been used in the study of a wide range of domains, including nonnociceptive sensory processing, depression, Alzheimer disease, aging, and epilepsy.
Chronic pain states also have altered brain neurochemical levels using $^1$H-MRS. Previous studies have shown negative associations between GABA and chronic pain. Similarly, acute pain stimulation leads to decreases in cerebral GABA and increases in Glx levels, although this may depend on the experimental pain modality used. However, most of the studies to date have included both younger and older individuals, raising the possibility that in older individuals, brain aging itself, and not chronic pain, may result in altered brain biochemistry. Previous studies indicate an age-related decline in cortical GABA levels, with lower frontal GABA levels being associated with worse cognitive performance. To the best of our knowledge, this is the first report of the relationship between GABA and Glx in prefrontal (ie, a region affected by aging processes and involved in the cognitive modulation of the pain experience) and sensorimotor (ie, a brain region involved in somatosensory and pain processing) brain regions. Based on the previous literature, we hypothesized that community-dwelling older adults with chronic musculoskeletal pain would exhibit lower GABA and higher Glx levels compared with younger and older controls. In addition, we hypothesized that GABA and Glx levels would be significantly associated with self-reported and experimental pain.

2. Methods

2.1. Participants

Community-dwelling younger (18–24 years old) and older (60–93 years old) individuals who spoke and understood written English were recruited and screened for a larger cross-sectional NIH-funded study at the University of Florida focused on the neurobiology of age-related differences in pain modulation (Neuro-modulatory Examination of Pain and Mobility Across the Lifespan). Potential participants were first screened over the phone and then again in person from the fall of 2015 to fall of 2019. We excluded individuals reporting any of the following conditions either over the phone screening or during the in-person baseline session: (1) Alzheimer, Parkinson, or other diagnosis of a nervous system disorder; (2) serious psychiatric conditions (eg, schizophrenia, major depression, or bipolar disorder); (3) uncontrolled hypertension (blood pressure >150/95 mm Hg), heart failure, or history of acute myocardial infarction; (4) systemic rheumatic disorders (ie, rheumatoid arthritis, systemic lupus erythematosus, or fibromyalgia); (5) chronic opioid use; (6) magnetic resonance imaging (MRI) contraindications; (7) excessive anxiety regarding protocol procedures; (8) hospitalization within the preceding year for psychiatric illness; (9) HIV or AIDS; and (10) cognitive impairment (Modified Mini-Mental State Examination (3MS) score $\leq$ 77). Younger adults were further excluded if they reported any chronic pain condition currently or in the past. All procedures were reviewed and approved by the University of Florida’s Institutional Review Board, and all participants provided verbal and written informed consent. We have previously reported on various aspects of the NEPAL study participants and its detailed methodology. To address the aims of this study, we included assessments of self-reported pain, depressive symptoms, a quantitative sensory testing battery, and MRS neuroimaging obtained from 3 separate laboratory visits.

2.1.1. Self-reported pain

Older participants were categorized to the pain group if they reported pain on most days during the past 3 months that interfered with their life consistent with the Task Force for the Classification of Chronic Pain consensus for the 11th version of the International Classification of Diseases of the World Health Organization. Pain categorization occurred after study completion and confirmed by a medical and pain history review. Participants were also asked about their average pain intensity in the past 3 months using an 11-point numerical rating scale (0 = no pain to 10 = the most intense pain imaginable), frequency of pain during the past week, pain duration, number of anatomical pain sites, as well as pharmacological and non-pharmacological treatments used in the past 3 months as part of a standardized pain history interview.

2.1.2. Depressive symptoms

The Center for Epidemiologic Studies Depression Scale questionnaire was used to measure the frequency of depressive symptoms during the past week on a 4-point Likert scale.

2.1.3. Quantitative sensory testing

Quantitative sensory testing (QST) was used to assess experimental pain sensitivity, similar to the methodology previously reported by our group in older individuals. Standardized testing was performed at the left thenar eminence and the first metatarsal head on all participants. Thermal pain thresholds were obtained with the TSA-II NeuroSensory Analyzer and accompanying software (Medoc Ltd, Ramat Yishai, Israel) using the method of limits.

Figure 1. Representative voxel placement from a single subject is superimposed in white, in both prefrontal (a) and sensorimotor (b) regions.
This procedure results in a QST profile with zero mean, 1SD. For clarity of data presentation, we adjusted the algebraic sign of Z-score values so that it reflects the participant’s sensitivity. Z-values above “0” indicates higher pain sensitivity, whereas Z-scores below “0” indicate lower pain sensitivity.

### 2.2.1. Neuroimaging session

Magnetic resonance imaging data were collected at the McKnight Brain Institute on the Advanced Magnetic Resonance Imaging and Spectroscopy facility’s Philips 3-Tesla scanner using a 32-channel radiofrequency coil. Participants were asked about their current pain intensity on the MRI table before starting the scanning procedures using a visual analogue scale (0–100). A T1-weighted anatomical image (magnetization-prepared rapid gradient-echo; repetition time/echo time = 7.2 ms/3.7 ms, 1-mm3 isotropic voxels) was acquired for MRS voxel placement and segmentation. GABA-edited MRS data were acquired using the MEGA-PRESS sequence.52 The prefrontal voxel was placed medial on the axial plane, aligned with the genu of the corpus callosum, inclusive of the pregenual ACC and medial prefrontal cortex (ie, mainly Brodmann areas 10 [ie, the anterior-most portion of the prefrontal cortex] and 32). When time allowed, we also collected data from the sensorimotor (S/M1) regions with the voxel centered over the hand knob area, parallel to the anterior–posterior axis. All voxels were 3 × 3 × 3 cm3 and representative voxel locations are shown in Figure 1. As part of the quality control procedures, voxel locations were verified after data collection to identify potential placement errors. Editing was performed with 14-ms sinc-Gaussian pulses applied at 1.9 ppm in the on experiment and 7.46 ppm in the off experiment. This editing scheme co-edits approximately 50% macromolecules at 3 ppm, which are coupled to spins at 1.7 ppm also inverted by editing pulses. Therefore, all GABA values reported refer to GABA + macromolecules. Acquisition details were repetition time per echo time of 2 seconds/68 ms, 320 transients with on-off scans alternating every 2 transients, a 16-step phase cycle (with steps repeated for on and off), 2048 data points acquired at a spectral width of 2 kHz, and variable pulse power and optimized relaxation delays water suppression.20 Quantitative analysis was performed using the Gannet program (version 2.0).12 All time domain data were frequency-corrected and phase-corrected using spectral registration,20 filtered with a 3-Hz exponential line broadening and zero filled by a factor of 16. Metabolite levels were fitted in the difference spectrum using simultaneous GABA 1 and glutamate and glutamine (Glx) signal fitting and both were broadening and zero filled by a factor of 16. Metabolite levels were fitted in the difference spectrum using simultaneous GABA + glutamate and glutamine (Glx) signal fitting and both were acceptable20 (Fig. 2). The GABA peak was fit using a 3-Gaussian function and a nonlinear baseline with the Glx signal at 3.75 ppm fit using nonlinear least squares fitting. The metabolite peaks were quantified relative to water (fit with a

| Table 1 | Tissue composition in the voxels across participants. |
|---------|-------------------------------------------------|
|         | Younger controls | Older controls | Older chronic pain | P      |
| Prefrontal voxel | n = 24 | n = 12 | n = 29 |   |
| Gray matter fraction | 0.586 ± 0.03 | 0.489 ± 0.04 | 0.505 ± 0.04 | 0.000 |
| White matter fraction | 0.288 ± 0.04 | 0.280 ± 0.04 | 0.287 ± 0.05 | 0.851 |
| Cerebrospinal fluid fraction | 0.125 ± 0.03 | 0.231 ± 0.07 | 0.208 ± 0.05 | 0.000 |
| Sensorimotor voxel | n = 12 | n = 5 | n = 14 |   |
| Gray matter fraction | 0.293 ± 0.05 | 0.216 ± 0.02 | 0.263 ± 0.03 | 0.003 |
| White matter fraction | 0.640 ± 0.06 | 0.644 ± 0.06 | 0.604 ± 0.05 | 0.234 |
| Cerebrospinal fluid fraction | 0.067 ± 0.02 | 0.140 ± 0.04 | 0.133 ± 0.05 | 0.000 |

Bold entries represent probability values less than 0.05.
Table 2

| Paired correlations between metabolite levels at the prefrontal and the sensorimotor voxels in a subset of participants (n = 31). | Probability | Probability |
|---|---|---|
| CSF-corrected GABA | 0.026 | 0.894 |
| Tissue-corrected GABA | −0.058 | 0.769 |
| CSF-corrected GABA | 0.380 | 0.046 |
| Tissue-corrected GABA | 0.368 | 0.054 |

Table 3

| Differences in demographic and clinical characteristics between the groups. | Younger controls (n = 23) | Older controls (n = 12) | Older chronic pain (n = 29) | P |
|---|---|---|---|---|
| Age, mean ± SD | 21.7 ± 1.8 | 73.7 ± 6.7 | 72.0 ± 7.1 | 0.001* |
| Sex, no. | | | | 0.458† |
| Male | 11 | 5 | 9 | |
| Female | 12 | 7 | 20 | |
| Race, no. | | | | 0.020† |
| Caucasian | 13 | 12 | 26 | |
| African American | 1 | 0 | 2 | |
| Asian | 1 | 0 | 0 | |
| Pacific Islander | 1 | 0 | 1 | |
| Hispanic | 7 | 0 | 0 | |
| Education, mean ± SD | 14.9 ± 1.5 | 16.4 ± 2.9 | 15.4 ± 2.6 | 0.187* |
| CES-D, mean ± SD | 7.6 ± 6.1 | 7.4 ± 3.3 | 7.9 ± 5.6 | 0.969* |
| No. of anatomical pain sites, mean ± SD | | | | | |
| Current pain at MRI (0–100), mean ± SD | 0.9 ± 4.1 | 0.9 ± 2.3 | 13.6 ± 16.0 | 0.001* |
| Ave. pain in the past 3 months (0–10), mean ± SD | 0 ± 0 | 0 ± 0 | 4.8 ± 2.1 | 0.001* |
| Pain days in past week (0–7), mean ± SD | | | | |
| Pain duration, mean ± SD | | | | 10.5 ± 2.1 |
| Narcotic (PRN), no. (%) | | | | 5 (17.2) |
| NSAID/Acetaminophen, no. (%) | | | | 16 (55.2) |
| Nonpharmacological interventions, no. (%) | | | | 18 (62.1) |

* Analysis of variance tests. Bold entries represent probability values less than 0.05.
† χ² tests.
CES-D, Center for Epidemiologic Studies Depression Scale; MRI, magnetic resonance imaging; NSAID, nonsteroidal anti-inflammatory drugs; PRN, as needed.
GABA levels were significantly greater than 3 SDs from the sample mean, whereas 1 younger adult reported a chronic pain condition (ie, migraine headaches). Thus, this study includes 64 participants with high-quality MRS data in a prefrontal voxel. In a subset (n = 31), data from a second voxel in the sensorimotor cortex were also obtained. Participants were between the ages of 19 and 94 years and were mostly non-Hispanic White (80.3%) and female (60.7%). Most of our older adults (65.9%) reported chronic musculoskeletal pain during the past 3 months with 2 pain problems on average that were most commonly reported in the legs or knees (85.2%) and back (55.6%) regions. Approximately 31% of participants (n = 9) reported their pain to be constant or continuous while 48% of participants (n = 14) reported their pain to be intermittent and 20% reported their pain had no predictable pattern (n = 6). Summary demographic and clinical characteristics are presented in Table 3.

3.1. Age differences in gamma-aminobutyric acid and glutamate and glutamine metabolite levels

3.1.1. Prefrontal CSF-corrected gamma-aminobutyric acid and glutamate and glutamine (n = 64)

There was a nonsignificant main effect of Age (F(1,59) = 1.3, P = 0.253, effect size = 0.022) and Age by Sex interaction (F(1,59) = 2.1, P = 0.155, effect size = 0.034) in prefrontal GABA. Similarly, there was a nonsignificant main effect of Age (F(1,59) = 1.1, P = 0.304, effect size = 0.009) and Age by Sex interaction (F(1,59) = 0.3, P = 0.609, effect size = 0.005) in prefrontal Glx.

Figure 3. Differences in sensorimotor GABA and Glx metabolite levels between older and younger participants. *Statistically significant post hoc comparisons at a probability less than 0.05. GABA, gamma-aminobutyric acid

Figure 4. Adjusted differences in CSF-corrected and tissue-corrected prefrontal GABA metabolite levels between the groups and stratified by sex. *Statistically significant post hoc comparisons at a probability less than or equal to 0.05. GABA, gamma-aminobutyric acid
3.1.2. Prefrontal tissue-corrected gamma-aminobutyric acid and glutamate and glutamine (n = 64)

There was a nonsignificant main effect of Age (F(1,59) = 0.8, P = 0.369, effect size = 0.014) and Age by Sex interaction (F(1,59) = 2.1, P = 0.150, effect size = 0.035) in prefrontal GABA. Similarly, there was a nonsignificant main effect of Age (F(1,59) = 0.6, P = 0.431, effect size = 0.011) and Age by Sex interaction (F(1,59) = 0.3, P = 0.599, effect size = 0.005) in prefrontal Glx.

3.1.3. Sensorimotor CSF-corrected gamma-aminobutyric acid and glutamate and glutamine (n = 31)

There was a significant main effect of Age (F(1,26) = 13.4, P = 0.001, effect size = 0.340) where older adults (n = 19) had lower sensorimotor GABA (M = 2.49, SEM = 0.05) compared with younger controls (n = 12, M = 2.78, SEM = 0.06, bootstrapped P = 0.002). There was no Age by Sex interaction in sensorimotor GABA (F(1,26) = 0.4, P = 0.540, effect size = 0.015). There was a significant main effect of Age group (F(1,26) = 5.4, P = 0.028, effect size = 0.172) where older adults (n = 19) had lower sensorimotor Glx (M = 3.9, SEM = 0.1) compared with younger controls (n = 12, M = 4.4, SEM = 0.2, bootstrapped P = 0.024, Fig. 3). There was no Age by Sex interaction in sensorimotor Glx (F(1,26) = 0.3, P = 0.561, effect size = 0.013).

3.1.4. Sensorimotor tissue-corrected gamma-aminobutyric acid and glutamate and glutamine (n = 31)

There was a significant main effect of Age (F(1,26) = 6.4, P = 0.018, effect size = 0.197) where older adults (n = 19) had lower sensorimotor GABA (M = 2.70, SEM = 0.05) compared with younger controls (n = 12, M = 2.93, SEM = 0.07, bootstrapped P = 0.037, Fig. 3). There was no Age by Sex interaction in sensorimotor GABA (F(1,26) = 0.5, P = 0.470, effect size = 0.023). There was a nonsignificant main effect of Age (F(1,26) = 3.1, P = 0.088, effect size = 0.108) and Age by Sex interaction in sensorimotor Glx (F(1,26) = 0.2, P = 0.649, effect size = 0.008).

3.2. Age and pain differences in gamma-aminobutyric acid and glutamate and glutamine metabolite levels

3.2.1. Prefrontal CSF-corrected gamma-aminobutyric acid and glutamate and glutamine (n = 64)

There was a significant main effect of Age-Pain (ie, comparing the 3 groups: younger controls, older controls, and older adults reporting pain) (F(2,57) = 3.2, P = 0.045, effect size = 0.103). Older individuals with chronic pain had significantly lower prefrontal GABA (M = 1.9, SEM = 0.2) compared with older controls (M = 2.6, SEM = 0.2, bootstrapped P = 0.027, Fig. 4). There was a trend for Age-Pain by Sex interaction (F(2,57) = 3.1, P = 0.050, effect size = 0.100, Figure 4) in prefrontal GABA. There was a
3.2.2. Prefrontal tissue-corrected gamma-aminobutyric acid and glutamate and glutamine (n = 64)

There was a significant main effect of Age-Pain (F(2,57) = 3.2, P = 0.049, effect size = 0.101). Older individuals with chronic pain had significantly lower prefrontal GABA (M = 2.2, SEM = 0.2) compared with older controls (M = 3.0, SEM = 0.3, bootstrapped P = 0.021, Fig. 4). There was a significant Age-Pain by Sex interaction (F(2,57) = 3.2, P = 0.039, effect size = 0.108) in prefrontal GABA where older males with chronic pain had significantly lower prefrontal GABA (M = 1.8, SEM = 0.3) compared with older (M = 3.3, SEM = 0.4, bootstrapped P = 0.022) and younger male controls (M = 3.0, SEM = 0.3, bootstrapped P = 0.028, Fig. 4). There was a nonsignificant main effect of Age-Pain (F(2,57) = 0.3, P = 0.711, effect size = 0.012) or Age-Pain by Sex interaction (F(2,57) = 0.3, P = 0.768, effect size = 0.010) in prefrontal Glx.

3.2.3. Sensorimotor CSF-corrected gamma-aminobutyric acid and glutamate and glutamine (n = 31)

There was a significant main effect of Age-Pain (F(2,24) = 16.8, P < 0.001, effect size = 0.583) where younger controls had significantly higher sensorimotor GABA (M = 2.8, SEM = 0.1) compared to older controls (M = 2.3, SEM = 0.1, bootstrapped P = 0.001) and older participants with chronic pain (M = 2.6, SEM = 0.1, bootstrapped P = 0.020, Fig. 5). There was not a significant Age-Pain by Sex interaction (F(2,24) = 2.3, P = 0.120, effect size = 0.162) in sensorimotor GABA. There was a nonsignificant main effect of Age-Pain (F(2, 24) = 2.6, P = 0.098, effect size = 0.176) or Age-Pain by Sex interaction (F(2,24) = 0.2, P = 0.794, effect size = 0.019) in sensorimotor Glx.

3.2.4. Sensorimotor tissue-corrected gamma-aminobutyric acid and glutamate and glutamine (n = 31)

There was a significant main effect of Age-Pain (F(2,24) = 7.4, P = 0.004, effect size = 0.414) where older controls had significantly lower sensorimotor GABA (M = 2.4, SEM = 0.1) compared with younger controls (M = 2.9, SEM = 0.1, bootstrapped P = 0.008, Fig. 5). There was not a significant Age-Pain by Sex interaction (F(2,24) = 0.6, P = 0.576, effect size = 0.051) in sensorimotor GABA. There was a nonsignificant main effect of Age-Pain (F(2,24) = 1.5, P = 0.254, effect size = 0.122) or Age-Pain by Sex interaction (F(2,24) = 0.5, P = 0.596, effect size = 0.048) in sensorimotor Glx.

3.3. Associations between prefrontal gamma-aminobutyric acid and glutamate and glutamine levels with clinical and experimental pain in older adults

Experimental pain thresholds by study group and test site are presented in Figure 6. Post hoc comparisons revealed older individuals with chronic pain had significantly lower pressure pain thresholds in the quadriceps (M = 426.1, SEM = 43.9) compared with young controls (M = 666.5, SEM = 63.3, bootstrapped P = 0.006, Fig. 6). Prefrontal GABA metabolite levels were inversely correlated with self-reported pain variables surviving both multiple comparison corrections as well as bootstrapping procedures controlling for race, sex, and age of the participants. Similarly, heat and cold pain thresholds were inversely associated with prefrontal GABA levels and these associations were supported by bootstrapping procedures (Fig. 7). However, cold pain thresholds did not survive multiple comparison corrections. Prefrontal GABA levels were not associated with pressure pain thresholds. Prefrontal Glx levels were not significantly associated with any of the variables of interest. Findings are summarized in Table 4. Owing to the small number of participants who had data in the sensorimotor voxel and self-reported and experimental pain measures, we did not examine associations between these variables.

4. Discussion

This study aimed to determine self-reported and experimental pain-related associations in brain levels of GABA and Glx, reflective of inhibitory and excitatory tone in community-dwelling older adults. Several key findings emerged. First, older adults with chronic pain had significantly lower prefrontal GABA levels that were driven, in part, by older males with chronic pain having lower levels of prefrontal GABA compared with younger and older male controls. Second, prefrontal, but not sensorimotor, GABA levels were associated with greater self-reported pain, greater pain...
frequency and duration, greater number of pain sites, and greater thermal pain sensitivity. Finally, prefrontal Glx levels were not associated with any self-reported or experimental pain characteristics in our older sample. Our findings suggest a key imbalance among inhibitory systems that may contribute to the increased prevalence of chronic pain in older individuals.

Our investigation furthers our understanding of the GABAergic and glutamatergic systems in the context of pain and aging brain processes. To the best of our knowledge, this is the first study to simultaneously examine clinical and experimental pain and their associations with GABA and Glx levels in a community-dwelling sample. Glutamate and GABA systems are key signal transducers in
GABA receptors are the most relevant GABA receptor subtypes for sensitivity. In healthy younger individuals, acute experimental pain with chronic musculoskeletal pain are consistent with the existing literature using 1H-MRS where reduced cerebral GABA levels have spinal analgesia. Future studies are needed to replicate the sex dysfunction. Indeed, work in mice expressing genetically engineered GABA receptors has shown that lower GABA levels in our older adults are in sharp contrast to findings in persons with migraine and chronic pelvic pain. Specifically, lower GABA levels were associated with greater self-reported pain, greater pain frequency and duration, greater number of reported pain sites, and greater thermal pain sensitivity. These findings are consistent with previous research where GABA levels correlate with clinical pain severity and experimental pain sensitivity. In healthy younger individuals, acute experimental pain stimulation has been found to change GABA levels in various brain regions. Specifically, administration of painful stimulation momentary decreased GABA levels in the anterior cingulate and occipital cortex, and tonic heat pain stimulation increased GABA levels in the prefrontal cortex. Although the above studies link cerebral GABA levels with chronic and acute pain processing, the directionality of the findings is less consistent. However, our findings are in sharp contrast to findings in persons with migraine and previous studies reporting associations between Glx concentrations and pain characteristics. This is likely due to the different brain regions investigated, different MRS acquisition and analyses parameters, and the age of the included participants. Most of the studies mentioned above have only included healthy younger individuals or a mixture of younger and older adults (except in knee osteoarthritis), which could account for these discrepancies because there are significant age-related changes in brain metabolite levels. In addition, we used a large prefrontal ROI covering several anatomically distinct brain areas, which are involved not only in descending inhibition but also in cognitive modulation through inhibitory GABAergic neurons. Furthermore, previous basic research showed hyperactivity in the amygdala leads to deactivation of prefrontal regions through GABAergic mechanisms emphasizing the need for studies in animal models. Future larger studies in humans must also differentiate between pain conditions in older vs younger populations and include appropriate age-control groups to examine metabolite levels across various regions.

Our study is limited by its small sample size, particularly with respect to older controls. This is not surprising given the high prevalence of chronic pain in older individuals, which further highlights the need to identify and study older adults without any chronic pain. Thus, future investigations in older adults should identify these true "control" groups. Second, the source of the Glx and GABA levels measured cannot be ascertained using 1H-MRS. Glx levels reflect the combination of glutamate (Glu) and glutamine (Gln) levels (ie, Glx = Glu + Gln). Thus, we cannot determine whether the Gln and Glu levels are in opposing directions or evaluate their levels separately. On the other hand, the GABA measured using 1H-MRS is believed to represent mostly GABA linked to the "tonic" or GABAergic inhibitory pathway. Nonetheless, the 1H-MRS signal arises from the gray and white matter and is an ensemble average of multiple different cell types, including astrocytes, glia, and neurons and has been reported across a number of domains to be associated with increased inhibitory capacity. Therefore, the metabolite signal might be at regions distant from the synapse. Animal studies are needed to determine the exact source and mechanism underlying the association of pain with these metabolites. Third, this is a cross-sectional study and no causal inferences can be made. It is not known whether younger and older individuals have predisposing mechanisms.
metabolite differences or whether the experience of pain or aging leads to such metabolite imbalances. Fourth, our older sample may not be representative of the general aging population because it included mostly Caucasian community-dwelling older individuals, who were cognitively intact and generally healthy. Longitudinal and basic studies including larger, more diverse samples with more severe pain and disability are needed to answer these questions in the context of an aging nervous system. Fifth, it is possible that our findings are driven by differences in momentary pain ratings, and future studies that test individuals with chronic pain when pain-free are needed to determine these associations. Furthermore, future studies should be designed to test whether medications taken by the study participants could drive potential metabolite differences, although our study participants were not taking medications affecting the GABAergic systems. Finally, given the small sample collected in the sensorimotor cortex, these findings, including the null findings, should be considered preliminary and require replication.

Despite these limitations, our study is the first to focus exclusively on age and pain differences including younger and older control cohorts, which is important to try to elucidate independent aging and pain contributions to brain GABAergic and glutamatergic processes. The present work includes 2 key neurochemicals to the forefront of our thinking regarding the molecular processes involved in chronic pain in older individuals. Our study supports prefrontal cortex GABA as a potential marker of pain severity and processing in chronic musculoskeletal pain states independent of age-related decline in these neurochemical systems. These findings may support the idea that GABAergic dysfunction in pain-processing brain networks may contribute to pain development and chronicity in older individuals.29 Finally, these data may also indicate that pharmacologic interventions that specifically target GABAergic neurotransmission may be an effective target in these older individuals with chronic musculoskeletal pain and lower brain GABA levels.

Disclosures
The authors have no conflicts of interest to declare.

Acknowledgements
The authors are grateful to our study volunteers for their participation and the NEPAL study team (Paige Lysne, Lorraine Hoyos, Darlin Ramirez, Brandon Apagueno, and Rachna Sannegowda). This work was supported by the National Institutes of Health (NIA K01AG048259, R01AG059809, and R01AG067757 to Y.C.A.; NIAAA K01AA025306 to E.P.; and NIA K01AG050707 to A.J.W.), the University of Florida Clinical Translational Sciences Institute (NCATS UL1TR001427), the Cognitive Aging and Memory Clinical Translational Program, McKnight Brain Foundation, and the University of Florida Claude D. Pepper Older Americans Independence Center (P30AG028740). This work applies tools developed under NIH R01EB016089, R01EB023693, and P41EB015909.

Article history:
Received 16 July 2020
Received in revised form 14 July 2021
Accepted 19 July 2021

References
[1] Aguila MER, Lagopoulos J, Leaver AM, Rebeck T, Hübser M, Brennan PC, Refshauge KM. Elevated levels of GABA+ in migraine detected using 1H-MRS. NMR Biomed 2015;28:890–7.
Prevalence and impact of pain in patients with migraine: response to levetiracetam treatment. Neuroreport 2017;28:1007–10.

Lytne P, Cohen R, Hoyos L, Fillingim RB, Riley JL, Cruz-Almeida Y. Age and pain differences in non-verbal fluency performance: associations with cortical thickness and subcortical volumes. Exp Gerontol 2019;126:110708.

Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed 1998;11:266–72.

Mescher M, Tannus A, Johnson N, Garwood M. Solvent suppression using selective echo dephasing. J Magn Reson Ser A, 123, 1996, 226–9, ISSN 1064-1858.

Mikkelsen M, Barker PB, Bhattacharya PK, Bex MK, Buur PF, Cecil KM, Chan KL, Chen DYT, Craven AR, Cuypers K, Dacko M, Duncan NW, Dydak U, Edmondson DA, Ende G, Ensland L, Gao F, Greenhouse I, Harris AD, He N, Heba S, Hoggard N, Hsu TW, Iansen JFA, Kangarlu A, Lange T, Lebel RM, Li Y, Lin CYE, Liu JK, Ling JF, Liu F, Ma R, Maes C, Moreno-Ortega M, Murray SO, Noah S, Noeske R, Noseworthy MD, Oeltzschner G, Prisciandaro JJ, Puts NAJ, Roberts TPL, Sailasuta N, Saleh MG, Schallmo MP, Simard N, Sillanpaa JT, Smith BH, Svensson P, Vlaeyen JWS, Wang SJ. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the international classification of diseases (ICD-11). PAIN 2019;160:19–27.

Price D, Solanky BS, Violante IR, Williams S, Wilson M. Current practice in magnetic resonance spectroscopy at 24 research sites. Neuroimage 2017;159:32–45.

Kwakowsky A. Sex- and age-related changes in GABA signaling in the human cortex. Biol Sex Differ 2019;10:5.

Lysne P, Cohen R, Hoyos L, Fillingim RB, Riley JL, Cruz-Almeida Y. Age and pain differences in non-verbal fluency performance: associations with cortical thickness and subcortical volumes. Exp Gerontol 2019;126:110708.

Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed 1998;11:266–72.

Mescher M, Tannus A, Johnson N, Garwood M. Solvent suppression using selective echo dephasing. J Magn Reson Ser A, 123, 1996, 226–9, ISSN 1064-1858.

Mikkelsen M, Barker PB, Bhattacharya PK, Bex MK, Buur PF, Cecil KM, Chan KL, Chen DYT, Craven AR, Cuypers K, Dacko M, Duncan NW, Dydak U, Edmondson DA, Ende G, Ensland L, Gao F, Greenhouse I, Harris AD, He N, Heba S, Hoggard N, Hsu TW, Iansen JFA, Kangarlu A, Lange T, Lebel RM, Li Y, Lin CYE, Liu JK, Ling JF, Liu F, Ma R, Maes C, Moreno-Ortega M, Murray SO, Noah S, Noeske R, Noseworthy MD, Oeltzschner G, Prisciandaro JJ, Puts NAJ, Roberts TPL, Sailasuta N, Saleh MG, Schallmo MP, Simard N, Sillanpaa JT, Smith BH, Svensson P, Vlaeyen JWS, Wang SJ. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the international classification of diseases (ICD-11). PAIN 2019;160:19–27.

Price D, Solanky BS, Violante IR, Williams S, Wilson M. Current practice in magnetic resonance spectroscopy at 24 research sites. Neuroimage 2017;159:32–45.

Kwakowsky A. Sex- and age-related changes in GABA signaling in the human cortex. Biol Sex Differ 2019;10:5.

Lysne P, Cohen R, Hoyos L, Fillingim RB, Riley JL, Cruz-Almeida Y. Age and pain differences in non-verbal fluency performance: associations with cortical thickness and subcortical volumes. Exp Gerontol 2019;126:110708.

Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed 1998;11:266–72.

Mescher M, Tannus A, Johnson N, Garwood M. Solvent suppression using selective echo dephasing. J Magn Reson Ser A, 123, 1996, 226–9, ISSN 1064-1858.